[Severe muscle disorders associated with statins: analysis of cases notified in France up to the end of February 2002 and data concerning the risk profile of cerivastatin].

After the withdrawal of cerivastatin from the market, a survey was performed concerning severe muscular disorders associated with statin treatments that were notified to the French national and pharmaceutical industry pharmacovigilance systems up to February 2002.
Among the 238 cases analysed, 69 were related to cerivastatin, 86 to simvastatin, 49 to pravastatin, 23 to atorvastatin and 9 to fluvastatin. The reporting rate was six- to ten-times higher for cerivastatin than for other statins. A major risk factor for rhabdomyolysis with cerivastatin was its association with gemfibrozil.
Postmarketing surveillance appears to be a major tool for early detection of safety problems with a new drug.
AuthorsMichel Andréjak, Valérie Gras, Jacques Caron
JournalTheĢrapie (Therapie) 2005 May-Jun Vol. 60 Issue 3 Pg. 299-304 ISSN: 0040-5957 [Print] England
Vernacular TitleAtteintes musculaires sévères sous statines: bilan des cas notifies en France jusqu'a fin février 2002 et données concernant les risques liés a la cérivastatine.
PMID16128274 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypolipidemic Agents
  • Pyridines
  • cerivastatin
  • Aged
  • Cross-Sectional Studies
  • Female
  • France (epidemiology)
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors (adverse effects)
  • Hypolipidemic Agents (adverse effects)
  • Male
  • Muscular Diseases (chemically induced, epidemiology)
  • Outpatients
  • Product Surveillance, Postmarketing
  • Pyridines (adverse effects)
  • Risk Assessment

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: